Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
The complement system has a key role in the innate immune system, and its dysregulation is involved in a wide range of diseases. Building on the success of pioneering drugs that specifically target the complement system to treat several rare diseases, there is growing interest in pursuing novel targets in the system and expanding the range of diseases in which complement-targeted drugs could be applied. This collection brings together a poster and a selection of recent reviews describing the role of the complement system in various diseases and the opportunities for therapeutic intervention.
The complement pathway plays key roles in host defence, but its excessive activation or dysregulation can lead to a variety of disorders. This poster overviews strategies to therapeutically intervene in the pathway and the new generation of complement inhibitors that are now in the clinic.
The complement system has a pivotal role in immunosurveillance and its dysregulation is involved in a variety of diseases. Here, Lambris and colleagues provide an overview of the pathological roles of the complement system in acute and chronic disorders, assessing recent developments in complement drug discovery, while highlighting the associated opportunities and challenges.
The complement system has a key role in inflammatory reactions that occur before, during and after transplantation. Here, the authors discuss this role and highlight current and future strategies to regulate complement activation and potentially improve outcomes in kidney transplantation.
In this review, the authors evaluate the association of complement activation with a variety of rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus and small-vessel vascultis, and discuss whether complement inhibition has therapeutic potential in these diseases.
Anaemia, thrombosis and smooth muscle dystonias are manifestations of paroxysmal nocturnal haemoglobinuria, a rare but potentially life-threatening haematological disorder. Inhibition of complement activation is the treatment of choice; stem cell transplantation is recommended for patients who also develop severe bone marrow failure.